Regulation of osteoclast function

Modern Rheumatology

Volumn 22, Issue 2, 2012, Pages 167-177

  Nakamura, Ichiro ^a   Takahashi, Naoyuki ^b   Jimi, Eijiro ^c   Udagawa, Nobuyuki ^b   Suda, Tatsuo ^d  

^a Yugawara   (Japan)

^b MATSUMOTO DENTAL UNIVERSITY   (Japan)

^c KYUSHU DENTAL COLLEGE   (Japan)

^d SAITAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Bone resorption; Integrin; Osteoclast; Rheumatoid arthritis

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CBL PROTEIN; COLONY STIMULATING FACTOR 1; DENOSUMAB; FOCAL ADHESION KINASE 2; INTERLEUKIN 1; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PLATELET DERIVED GROWTH FACTOR; PROTEIN P130; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; VITRONECTIN RECEPTOR;

CELL ACTIVATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL MATURATION; CELL POLARITY; CELL SURVIVAL; EXTRACELLULAR MATRIX; HOMEOSTASIS; HUMAN; MOLECULAR MECHANICS; ONCOGENE SRC; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

ARTHRITIS, RHEUMATOID; BONE DEVELOPMENT; BONE RESORPTION; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HUMANS; JOINTS; OSTEOCLASTS; SIGNAL TRANSDUCTION;

EID: 84861483772     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.1007/s10165-011-0530-8     Document Type: Review

References (87)

1. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev. 1999;20:345-57. (Pubitemid 30649812)
2. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504-8.
3. Nakamura I, Rodan GA, Duong LT. Regulatory mechanism of osteoclast activation. J Electron Microsc. 2003;52:527-33. (Pubitemid 38092540)
4. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, et al. Osteoblastic cells are involved in osteoclast formation. Endocrinology. 1988;123:2600-2.
5. Tezuka K, Sato T, Kamioka H, Nijweide PJ, Tanaka K, Matsuo T, et al. Identification of osteopontin in isolated rabbit osteoclasts. Biochem Biophys Res Commun. 1992;186:911-7.
6. 3 in osteoclast differentiation and function. In: McCormick DB, Suttie JW, Wagner C, editors. Methods in enzymology, vitamins and coenzymes, vol 282. San Diego: Academic Press; 1997. pp. 223-35.
7. Wesolowski G, Duong LT, Lakkakorpi PT, Nagy RM, Tezuka K, Tanaka H, et al. Isolation and characterization of highly enriched, prefusionmouse osteoclastic cells. Exp Cell Res. 1995;219:679-86.
8. Jimi E, Nakamura I, Amano H, Taguchi Y, Tsurukai T, Tamura M, et al. Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell contact. Endocrinology. 1996;37:2187-90. (Pubitemid 26133995)
9. Tanaka S, Takahashi T, Takayanagi H, Miyazaki T, Oda H, Nakamura K, et al. Modulation of osteoclast function by adenovirus vector-induced epidermal growth factor receptor. J Bone Miner Res. 1998;13:1714-20. (Pubitemid 28492001)
10. Duong LT, Nakamura I, Lakkakorpi PT, Bett AJ, Lipfert L, Rodan GA. Inhibition of osteoclast function by adenovirus expressing antisense PYK2. J Biol Chem. 2001;276:7484-92.
11. Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res. 1997;12:869-79. (Pubitemid 27224995)
12. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okumuram H, et al. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature. 1990;345:442-4. (Pubitemid 120014957)
13. Fuller K, Owens JM, Jagger CJ, Wilson A, Moss R, Chambers TJ. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J Exp Med. 1993;178:1733-44. (Pubitemid 23318452)
14. Jimi E, Shuto T, Koga T. Macrophage colony-stimulating factor and interleukin-1α maintain the survival of osteoclast-like cells. Endocrinology. 1995;136:808-11.
15. Jimi E, Nakamura I, Duong LT, Ikebe T, Takahashi N, Rodan GA, et al. Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/ stromal cells. Exp Cell Res. 1999;247:84-93. (Pubitemid 29393964)
16. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis - inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA. 1998;95:3597-602.
17. Lacey DL, Timms E, Tan HL, Kelley M, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93:165-76. (Pubitemid 28180851)
18. Jimi E, Akiyama S, Tsurukai T, Okahashi N, Kobayashi K, Udagawa N, et al. Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J Immunol. 1999;163:434-42. (Pubitemid 29295871)
19. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/ RANKL-RANK interaction. J Exp Med. 2000;191:275-86.
20. Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F, et al. Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med. 2005;202:589-95. (Pubitemid 41248411)
21. Stanley ER, Berg KL, Einstein DB, Lee PS, Pixley FJ, Wang Y, et al. Biology and action of colony-stimulating factor-1. Mol Reprod Dev. 1997;46:4-10. (Pubitemid 27021347)
22. Felix R, Cecchini MG, Fleisch H. Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology. 1990;127:2592-4. (Pubitemid 20381799)
23. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-9. (Pubitemid 27507987)
24. Wong BR, Rho J, Arron J, Robinson E, Orlinick J, Chao M, et al. TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J Biol Chem. 1997;272:25190-4. (Pubitemid 27415705)
25. Jones SJ, Boyde A, Ali NN. The resorption of biological and non-biological substrates by cultured avian and mammalian osteoclasts. Anat Embryol (Berl). 1984;170:247-56. (Pubitemid 15208293)
26. Jones SJ, Boyde A, Ali NN, Maconnachie E. A review of bone cell and substratum interactions. Scanning. 1985;7:5-24.
27. Chambers TJ, Thomson BM, Fuller K. Effect of substrate composition on bone resorption by rabbit osteoclasts. J Cell Sci. 1984;70:61-71. (Pubitemid 15220225)
28. Silver IA, Murrills RJ, Etherington DJ. Microelectrode studies on the acid microenvironment beneath adherent macrophages and osteoclasts. Exp Cell Res. 1988;175:266-76.
29. Destaing O, Saltel F, Géminard JC, Jurdic P, Bard F. Podosomes display actin turnover and dynamic self-organization in osteoclasts expressing actin-green fluorescent protein. Mol Biol Cell. 2003;14:407-16. (Pubitemid 36237005)
30. Jurdic P, Saltel F, Chabadel A, Destaing O. Podosome and sealing zone: specificity of the osteoclast model. Eur J Cell Biol. 2006;85:195-202.
31. Lakkakorpi PT, Väänänen H. Kinetics of the osteoclast cyto-skeleton during the resorption cycle in vitro. J Bone Miner Res. 1991;6:817-26.
32. Nakamura I, Takahashi N, Sasaki T, Tanaka S, Udagawa N, Murakami H, et al. Wortmannin, a specific inhibitor of phosphatidylinositol- 3 kinase, blocks osteoclastic bone resorption. FEBS Lett. 1995;361:79-84.
33. Nakamura I, Takahashi N, Sasaki T, Jimi E, Kurokawa T, Suda T. Chemical and physical properties of the extracellular matrix are required for the actin ring formation in osteoclasts. J Bone Miner Res. 1996;12:1873-9. (Pubitemid 26425679)
34. Suzuki H, Nakamura I, Takahashi N, Ikuhara T, Matsuzaki K, Isogai Y, et al. Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology. 1996;137:4685-90. (Pubitemid 26403306)
35. Murakami H, Takahashi N, Sasaki T, Udagawa N, Tanaka S, Nakamura I, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. 1995;17:137-44.
36. Woo JT, Kawatani M, Kato M, Shinki T, Yonezawa T, Kanoh N, et al. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proc Natl Acad Sci USA. 2006;103:4729-34.
37. Fuller K, Ross JL, Szewczyk KA, Moss R, Chambers TJ. Bone is not essential for osteoclast activation. PLoS One. 2010;5:e12837.
38. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 1992;69:11-25.
39. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science. 1995;268:233-9.
40. Horton MA, Rodan GA. Integrins as therapeutic targets in bone disease. In: Horton MA, editor. Adhesion receptors as therapeutic targets. Boca Raton: CRC Press Inc., 1996. pp. 223-245.
41. 3 integrins "vitronectin receptor". Int J Biochem Cell Biol. 1997;29:721-5.
42. Chambers TJ, Fuller K, Darby JA, Pringle JAS, Horton MA. Monoclonal antibodies against osteoclasts inhibit bone resorption in vivo. Bone Miner. 1986;1:127-35. (Pubitemid 16018088)
43. Davies J, Warwick J, Totty N, Philp R, Helfrich M, Horton M. The osteoclasts functional antigen, implicated in the regulation of bone resorption, is biochemically related to the vitronectin receptor. J Cell Biol. 1989;109:1817-26. (Pubitemid 19251227)
44. Sato M, Sardana MK, Grasser WA, Garsky VM, Murray JM, Gould RJ. Echistatin is a potent inhibitor of bone resorption in culture. J Cell Biol. 1990;111:1713-23.
45. Clover J, Dodds RA, Gowen M. Integrin subunit expression by human osteoblasts and osteoclasts in situ and in culture. J Cell Sci. 1992;103:267-71.
46. Horton MA, Taylor ML, Arnett TR, Helfrich MH. Arg-Gly-Asp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts. Exp Cell Res. 1991;195:368-75. (Pubitemid 121006336)
47. Fisher JE, Caulfield M, Sato M, Quartuccio HA, Gould RH, Garsky VM, et al. Inhibition of osteoclastic bone resorption in vivo by echistatin, an "arginyl-glycyl-aspartyl"(RGD)-containing protein. Endocrinology. 1993;132:1411-3. (Pubitemid 23068668)
48. 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest. 1997;99:2284-92.
49. Masarachia P, Yamamoto M, Leu C-T, Rodan G, Duong LT. Histomorphometric evidence for echistatin inhibition of bone resorption in mice with secondary hyperparathyroidism. Endocrinology. 1998;139:1401-10. (Pubitemid 28510162)
50. Crippes BA, Engleman VW, Settle SL, Delarco J, Ornberg RL, Helfrich MH, et al. Antibody to beta(3) integrin inhibits osteoclast- mediated bone resorption in the thyroparathyroidectomized rat. Endocrinology. 1996;137:918-24. (Pubitemid 26074132)
51. Yamamoto M, Fisher JE, Gentile M, Seedor JG, Leu C-T, Rodan SB, et al. The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats. Endocrinology. 1998;139:1411-9. (Pubitemid 28510163)
52. 3 integrins are osteosclerotic because of dysfunctional osteoclasts. J Clin Invest. 2000;105:433-40.
53. Soriano P, Montgomery C, Geske R, Bradley A. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell. 1991;64:693-702. (Pubitemid 121001157)
54. Thomas SM, Brugge JS. Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997;13:513-609. (Pubitemid 28034534)
55. c-src, preferentially on ruffled border membranes. FEBS Lett. 1992;313:85-9.
56. c-src in association with intracellular membranes. J Cell Biol. 1992;119:1003-13.
57. c-src expression for osteoclasts to form ruffled border and resorb bone in mice. J Clin Invest. 1992;90:1622-7.
58. Lowe C, Yoneda T, Boyce BF, Chen H, Mundy GR. Osteopetrosis in c-src-deficient mice is due to an autonomous defect of osteoclasts. Proc Natl Acad Sci USA. 1993;90:4485-9. (Pubitemid 23148929)
59. Cas is involved in actin organization in osteoclasts. J Biol Chem. 1998;273: 11144-9.
60. 3 integrin- and M-CSF-mediated signals in osteoclasts: the involvement of phospholipase-Cγ. J Cell Biol. 2001;152:361-73.
61. Schwartzberg PL, Xing L, Hoffmann O, Lowell CA, Garrett L, Boyce BF, et al. Rescue of osteoclast function by transgenic expression of kinase-deficient Src in src-/- mutant mice. Genes Dev. 1997;11:2835-44. (Pubitemid 27481684)
62. Xing L, Venegas AM, Chen A, Garrett-Beal L, Boyce BF, Vermas HE, et al. Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival. Genes Dev. 2001;15:241-53. (Pubitemid 32107668)
63. Miyazaki T, Takayanagi H, Isshiki M, Takahashi T, Okada M, Fukui Y, et al. In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene. J Bone Miner Res. 2000;15:41-51. (Pubitemid 30026931)
64. Miyazaki T, Sanjay A, Neff L, Tanaka S, Horne WC, Baron R. Src kinase activity is essential for osteoclast function. J Biol Chem. 2004;279:17660-6. (Pubitemid 38560531)
65. Tanaka S, Amling M, Neff L, Peyman A, Uhlmann E, Levy JB, et al. c-Cbl is downstream of c-Src in a signaling pathway necessary for bone resorption. Nature. 1996;383:528-31. (Pubitemid 26346179)
66. Murphy MA, Schnall RG, Venter DJ, Barnett L, Bertoncello I, Thien CB, et al. Tissue hyperplasia and enhanced T-cell signalling via ZAP-70 in c-Cbl-deficient mice. Mol Cell Biol. 1998;18:4872-82. (Pubitemid 28343071)
67. Nakajima A, Sanjay A, Chiusaroli R, Adapala NS, Neff L, Itzsteink C, et al. Loss of Cbl-b increases osteoclast bone-resorbing activity and induces osteopenia. J Bone Miner Res. 2009;24:1162-72.
68. Joazeiro CAP, Wing SS, Huang H-K, Leverson JD, Hunter T, Liu Y-C. The tyrosine kinase negative regulator c-Cbl as a RING-type, E2-dependent ubiquitin-protein ligase. Science. 1999;286: 309-12. (Pubitemid 29484697)
69. Lee PSW, Wang Y, Dominguez MG, Yeung Y-G, Murphy MA, Bowtell DDL, et al. The Cbl protooncoprotein stimulates CSF-1 receptor multiubiquitination and endocytosis, and attenuates macrophage proliferation. EMBO J. 1999;18:3616-28. (Pubitemid 29308842)
70. Yokouchi M, Kondo T, Sanjay A, Houghton A, Yoshimura A, Komiya S, et al. Src-catalyzed phosphorylation of c-Cbl leads to the interdependent ubiquitination of both proteins. J Biol Chem. 2001;276:35185-93.
71. Duong LT, Lakkakorpi PT, Nakamura I, Machwate M, Nagy RM, Rodan GA. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by avb3 integrin, and associated with SRC kinase. J Clin Invest. 1998;102:881-92. (Pubitemid 28419233)
72. Schlaepfer DD, Hunter T. Integrin signalling and tyrosine phosphorylation: just the FAKs? Trends Cell Biol. 1998;8:151-7. (Pubitemid 28142262)
73. Gil-Henn H, Destaing O, Sims NA, Aoki K, Alles N, Neff L, et al. Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in Pyk2(-/-) mice. J Cell Biol. 2007;178:1053-64. (Pubitemid 47443326)
74. Buckbinder L, Crawford DT, Qi H, Ke HZ, Olson LM, Long KR, et al. Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosis. Proc Natl Acad Sci USA. 2007;104:10619-24. (Pubitemid 47185714)
75. Sakai R, Iwamatsu A, Hirano N, Ogawa S, Tanaka T, Mano H, et al. A novel signaling molecule, p130, forms stable complexes in vivo with v-Crk and v-Src in a tyrosine phosphorylation-dependent manner. EMBO J. 1994;13:3748-56. (Pubitemid 24275020)
76. Lakkakorpi PT, Nakamura I, Nagy RM, Parsons JT, Rodan GA, Duong LT. Stable association of PYK2 and p130(Cas) in osteoclasts and their co-localization in the sealing zone. J Biol Chem. 1999;274:4900-7.
77. Honda H, Oda H, Nakamoto T, Honda Z, Sakai R, Suzuki T, et al. Cardiovascular anomaly, impaired actin bundling and resistance to Src-induced transformation in mice lacking p130Cas. Nat Genet. 1998;19:361-5. (Pubitemid 28357908)
78. Sawada Y, Tamada M, Dubin-Thaler BJ, Cherniavskaya O, Sakai R, Tanaka S, et al. Force sensing by mechanical extension of the Src family kinase substrate p130Cas. Cell. 2006;127:1015-26. (Pubitemid 44803062)
79. Zhang D, Udagawa N, Nakamura I, Murakami H, Saito S, Yamasaki K, Shibasaki Y, Morii N, Narumiya S, Takahashi N, et al. The small GTP-binding protein, rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci. 1995;108:2285-92.
80. Faccio R, Teitelbaum SL, Fujikawa K, Chappel J, Zallone A, Tybulewicz VL, et al. Vav3 regulates osteoclast function and bone mass. Nat Med. 2005;11:284-90. (Pubitemid 40460556)
81. Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, et al. Tumor necrosis factor receptor-associated factor (TRAF) family: adaptor proteins that mediate cytokine signaling. Exp Cell Res. 2000;254:14-24. (Pubitemid 30066727)
82. Lomaga MA, Yeh W-C, Sarosi I, Duncan GS, Furlonger C, Ho A, et al. TRAF6 deficiency results in osteopetrosis and defective interlerkin-1, CD40, and LPS signaling. Genes Dev. 1999;13:1015-24. (Pubitemid 29200984)
83. Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells. 1999;4:353-62. (Pubitemid 29359450)
84. Nakamura I, Kadono Y, Takayanagi H, Jimi E, Miyazaki T, Oda H, et al. IL-1 regulates cytoskeletal organization in osteoclasts via TNF receptor-associated factor 6/c-Src complex. J Immunol. 2002;168:5103-9. (Pubitemid 34495974)
85. Wong BR, Besser D, Kim N, Arron JR, Vologodskaia M, Hanafusa H, et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell. 1999;4:1041-9. (Pubitemid 30054909)
86. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 2000;43:259-69. (Pubitemid 30395733)
87. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum. 2008;58:1299-309. (Pubitemid 351705919)